CIK 0001664710
- Non-accelerated filer
- Smaller reporting company
Keros Therapeutics, Inc.
Sign in to watch- Ticker
- KROS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 811173868
- Phone
- +1 617-314-6297
- Business address
- 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,619
- in 1 filing, $6K under 10b5-1 plans
Net −$5,619. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-04-13 | Arkin Bio Ventures Limited Partnership 10% owner | Conversion · Series B-1 Preferred Stock | −343,270 | 0 | ||
| 2020-04-13 | Arkin Bio Ventures Limited Partnership 10% owner | Conversion · Series C Preferred Stock | −167,537 | 0 | ||
| 2020-04-07 | Seehra Jasbir Chief Executive Officer | Grant or award · Employee Stock Option (right to buy) | +696,569 | 696,569 | ||
| 2020-04-07 | Regnante Keith Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +18,430 | 18,430 | ||
| 2020-04-07 | Regnante Keith Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +133,622 | 133,622 | ||
| 2020-04-07 | Ordonez Claudia Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +18,430 | 18,430 | ||
| 2020-04-07 | Lachey Jennifer Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +241,222 | 241,222 |
Page 36 of 36 · 707 trades